Javascript must be enabled to continue!
Mortality rate and predictors among patients with breast cancer at a referral hospital in northwest Ethiopia: A retrospective follow-up study
View through CrossRef
Background
Breast cancer is one of the common global health concerns that affects2.1 million women each year and causes the highest number of cancer-related morbidity and mortality among women. The objective of this study was to determine the mortality rate and its predictors among breast cancer patients at the referral hospitals, in northwest Ethiopia.
Methods
A retrospective follow-up study was conducted on breast cancer patients registered between February 01, 2015 and February 28, 2018. They were selected by simple random sampling using computer-generated method and followed until February 29, 2020, in Amhara region referral hospital. A pre-tested data extraction checklist was used to collect data from the registration book and patient medical records. The collected data were entered into Epi-Data version 3.1 and exported to STATA version 14 for analysis. The mortality rate by person-year observation was computed. The Kaplan-Meier survival curve with the log-rank test was used to estimate the survival probabilities of the patients. Bivariate and multivariate Cox regression model was used to identify predictors of mortality.
Results
The overall mortality rate of breast cancer was 16.9 per 100 person-years observation. The median survival time was 38.3 (IQR: 26.23, 49.4) months. Independent predictors of breast cancer mortality was; Clinical stage IV and stage III (aHR:10.44,95% CI: 8.02,11.93 and aHR: 9.43, 95% CI: 6.29,11.03respectively), number of positive lymph node in the category of 10 and more and number of positive lymph node within the category of 4–9 (aHR:12.58, 95%CI: 5.2, 30.46 and aHR: 4.78, 95% CI: 2.19, 10.43respectively), co-morbidities (aHR:1.5, 95%CI: 1.01,2.21), Postmenopausal (aHR:2.03,95% CI: 1.37, 3), histologic grade III (aHR:2.12, 95% CI: 1.26,3.55) and not received hormonal therapy (aHR: 2.19, 95%CI: 1.52,3.15) were independent predictors of mortality.
Conclusion
The overall mortality rate was 16.9 per 100 person-years. The finding was higher compared to high-income countries. Advanced clinical stage, co-morbidities, menopausal status, and hormonal therapy are the significant predictors of mortality. Early detection and treatment of breast cancer is needed to reduce the mortality rate.
Public Library of Science (PLoS)
Title: Mortality rate and predictors among patients with breast cancer at a referral hospital in northwest Ethiopia: A retrospective follow-up study
Description:
Background
Breast cancer is one of the common global health concerns that affects2.
1 million women each year and causes the highest number of cancer-related morbidity and mortality among women.
The objective of this study was to determine the mortality rate and its predictors among breast cancer patients at the referral hospitals, in northwest Ethiopia.
Methods
A retrospective follow-up study was conducted on breast cancer patients registered between February 01, 2015 and February 28, 2018.
They were selected by simple random sampling using computer-generated method and followed until February 29, 2020, in Amhara region referral hospital.
A pre-tested data extraction checklist was used to collect data from the registration book and patient medical records.
The collected data were entered into Epi-Data version 3.
1 and exported to STATA version 14 for analysis.
The mortality rate by person-year observation was computed.
The Kaplan-Meier survival curve with the log-rank test was used to estimate the survival probabilities of the patients.
Bivariate and multivariate Cox regression model was used to identify predictors of mortality.
Results
The overall mortality rate of breast cancer was 16.
9 per 100 person-years observation.
The median survival time was 38.
3 (IQR: 26.
23, 49.
4) months.
Independent predictors of breast cancer mortality was; Clinical stage IV and stage III (aHR:10.
44,95% CI: 8.
02,11.
93 and aHR: 9.
43, 95% CI: 6.
29,11.
03respectively), number of positive lymph node in the category of 10 and more and number of positive lymph node within the category of 4–9 (aHR:12.
58, 95%CI: 5.
2, 30.
46 and aHR: 4.
78, 95% CI: 2.
19, 10.
43respectively), co-morbidities (aHR:1.
5, 95%CI: 1.
01,2.
21), Postmenopausal (aHR:2.
03,95% CI: 1.
37, 3), histologic grade III (aHR:2.
12, 95% CI: 1.
26,3.
55) and not received hormonal therapy (aHR: 2.
19, 95%CI: 1.
52,3.
15) were independent predictors of mortality.
Conclusion
The overall mortality rate was 16.
9 per 100 person-years.
The finding was higher compared to high-income countries.
Advanced clinical stage, co-morbidities, menopausal status, and hormonal therapy are the significant predictors of mortality.
Early detection and treatment of breast cancer is needed to reduce the mortality rate.
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract
IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract
Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Abstract
Introduction
Fine-needle aspiration (FNA) is commonly used to investigate lymphadenopathy of suspected metastatic origin. The current study aims to find the association be...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

